Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Ipilimumab and Nivolumab for Patients With High-risk Uveal Melanoma

NCT07501117 is registered in ClinicalTrials.gov with Inge Marie Svane as lead sponsor.

NCT NCT07501117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07501117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Ipilimumab and Nivolumab for Patients With High-risk Uveal Melanoma
Lead sponsor
Inge Marie Svane
Phase
Phase 1
Overall status
Recruiting
Start date
June 29, 2026
Completion date
June 1, 2029
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

uveal melanoma